Poly Medicure Limited has informed the Exchange about General Updates
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure reported strong FY25 results with consolidated revenue growing 21.4% to Rs 1,669.8 crore and PAT jumping 31.1% to Rs 338.6 crore. EBITDA grew 26.6% to Rs 452.8 crore, with margins expanding 113 basis points to 27.1%, reflecting improved operating efficiency. The company has zero net debt and a healthy cash position of Rs 1,219.6 crore, bolstered by a QIP raised in August 2024. Q4 also showed robust performance with revenue up 16.6% and PAT up 34.3% YoY. Key growth drivers include the commercial launch of a drug-eluting stent, 30+ new product launches in FY25, and strong export revenue growth of 24%. The company is the second-fastest growing medtech firm in India with 12 manufacturing plants across 4 countries and 334 patents.
Strong financial performance with margin expansion, zero debt, and large cash reserves signals a financially robust company. Continued growth in exports and new product launches in transformative areas like cardiology and critical care could support future earnings growth, making this positive for shareholders.